Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
56 hedge funds and large institutions have $59.4M invested in Aevi Genomic Medicine Inc in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 10 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 13
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 63 → 56 (-7)
27% less capital invested
Capital invested by funds: $81.6M → $59.4M (-$22.2M)
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.44M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$690K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$229K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$216K |
| 5 |
State Street
Boston,
Massachusetts
|
+$146K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$2.17M |
| 2 |
SIM
Spark Investment Management
New York
|
-$465K |
| 3 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
-$391K |
| 4 |
Millennium Management
New York
|
-$196K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$132K |
GNMX Hedge Fund Activity: Q1 2016 in Review
56 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q1 2016, worth a combined $59.4M — down 27% from $81.6M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of GNMX and 3 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 18 added.
The largest buyer was Adage Capital Partners, adding an estimated $1.44M. The largest seller was Baillie Gifford & Co, exiting entirely with an estimated $2.17M sold.
- 56 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q1 2016, down from 63 in Q4 2015.
- Funds reported $59.4M of Aevi Genomic Medicine Inc stock for Q1 2016, down 27% quarter-over-quarter.
- 3 funds opened new Aevi Genomic Medicine Inc positions in Q1 2016 and 10 closed out, a net change of -7 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q1 2016 was Adage Capital Partners, an estimated $1.44M added.
- The largest Aevi Genomic Medicine Inc seller in Q1 2016 was Baillie Gifford & Co, an estimated $2.17M sold.
Based on aggregated 13F filings for Q1 2016.